Product Name
EXOSC3, siRNA
Full Product Name
EXOSC3 siRNA (Mouse)
Product Synonym Names
RRP40; Exosome complex component RRP40; Exosome component 3; Ribosomal RNA-processing protein 40
Product Gene Name
EXOSC3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q7TQK4
Specificity
EXOSC3 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse EXOSC3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of EXOSC3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
EXOSC3 sirna
siRNA to inhibit EXOSC3 expression using RNA interference
Applications Tested/Suitable for EXOSC3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for EXOSC3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_079789.1
[Other Products]
NCBI GenBank Nucleotide #
NM_025513.3
[Other Products]
UniProt Primary Accession #
Q7TQK4
[Other Products]
UniProt Secondary Accession #
Q9CV81; Q9CVW2[Other Products]
UniProt Related Accession #
Q7TQK4[Other Products]
Molecular Weight
29,546 Da
NCBI Official Full Name
exosome complex component RRP40
NCBI Official Synonym Full Names
exosome component 3
NCBI Official Symbol
Exosc3 [Similar Products]
NCBI Official Synonym Symbols
Rrp40; AI593501; 2310005D06Rik
[Similar Products]
NCBI Protein Information
exosome complex component RRP40
UniProt Protein Name
Exosome complex component RRP40
UniProt Synonym Protein Names
Exosome component 3; Ribosomal RNA-processing protein 40
Protein Family
Exosome complex component
UniProt Gene Name
Exosc3 [Similar Products]
UniProt Synonym Gene Names
Rrp40 [Similar Products]
UniProt Entry Name
EXOS3_MOUSE
UniProt Comments for EXOSC3
EXOSC3: Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defects, thereby limiting or excluding their export to the cytoplasm. The RNA exosome may be involved in Ig class switch recombination (CSR) and/or Ig variable region somatic hypermutation (SHM) by targeting AICDA deamination activity to transcribed dsDNA substrates. In the cytoplasm, the RNA exosome complex is involved in general mRNA turnover and specifically degrades inherently unstable mRNAs containing AU-rich elements (AREs) within their 3' untranslated regions, and in RNA surveillance pathways, preventing translation of aberrant mRNAs. It seems to be involved in degradation of histone mRNA. The catalytic inactive RNA exosome core complex of 9 subunits (Exo-9) is proposed to play a pivotal role in the binding and presentation of RNA for ribonucleolysis, and to serve as a scaffold for the association with catalytic subunits and accessory proteins or complexes. EXOSC3 as peripheral part of the Exo-9 complex stabilizes the hexameric ring of RNase PH-domain subunits through contacts with EXOSC9 and EXOSC5. Defects in EXOSC3 are the cause of pontocerebellar hypoplasia type 1B (PCH1B). A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement. Belongs to the RRP40 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Nucleolus; Ribonuclease; EC 3.1.13.-; RNA processing
Cellular Component: cytoplasm; nucleolus; exosome (RNase complex); nucleus; nuclear exosome (RNase complex)
Molecular Function: 5'-3' exoribonuclease activity; 3'-5'-exoribonuclease activity; nuclease activity; hydrolase activity; RNA binding; exonuclease activity
Biological Process: positive regulation of isotype switching; isotype switching; exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA); DNA deamination; rRNA processing
Research Articles on EXOSC3
1. EXOSC3 mutations account for 30%-40% of patients with PCH1 with variability in survival and clinical severity that is correlated with the genotype.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
